The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis

Table 1 Characteristics of eligible studies in the meta-analysis

Study	EMERALD	SERENA-2	AMEERA-3	acelELA
First author	Francois-Clement Bidard	Mafalda Oliveira	Sara M. Tolaney	Miguel Martin
Year of publication	2022	2022	2023	2022
Phase	III	II	II	II
Patients, n	477	220	290	303
Patients	Men or postmenopausal women	Postmenopausal women	Men or women (any menopausal status)	Men or women (any menopausal status)
Oral SERD regimen/dose	Elacestrant/400 mg	Camizestrant/75 mg (A)^a/ 150 mg (B)^a	Amcenestrant/400 mg	Giredestrant/30 mg
Standard-of-care ET	SOC	Fulvestrant	TPC	PCET
ESR1m, n	228	68	120	90
Prior CDK4/6i, %	Required, 100	Permitted, 49.6	Permitted, 79	Permitted, 42
Allowed prior fulvestrant	Yes	No	Yes	Yes
HR	0.70	0.58 (75 mg)/0.67 (150 mg)	1.051	0.81
95% CI	0.55-0.88	0.41-0.81 (75 mg)/0.48-0.92 (150 mg)	0.789-1.40	0.60-1.01

Abbreviations: SOC Standard-of-care, TPC Treatment of physician’s choice, PCET Physician’s choice of endocrine monotherapy
^aSERENA-2 was divided into two cohorts because the comparisons were between two doses of camizestrant 75 mg and 150 mg

ISSN: 1471-2407